PRPH Stock Overview
Develops and commercializes novel drugs, dietary supplements, and compounds in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
ProPhase Labs, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.72 |
| 52 Week High | US$7.48 |
| 52 Week Low | US$0.61 |
| Beta | -0.30 |
| 1 Month Change | -6.79% |
| 3 Month Change | -68.02% |
| 1 Year Change | -84.08% |
| 3 Year Change | -90.29% |
| 5 Year Change | -60.38% |
| Change since IPO | 43.90% |
Recent News & Updates
Investors Give ProPhase Labs, Inc. (NASDAQ:PRPH) Shares A 65% Hiding
Nov 09
It's Down 65% But ProPhase Labs, Inc. (NASDAQ:PRPH) Could Be Riskier Than It Looks
Nov 09Recent updates
Investors Give ProPhase Labs, Inc. (NASDAQ:PRPH) Shares A 65% Hiding
Nov 09It's Down 65% But ProPhase Labs, Inc. (NASDAQ:PRPH) Could Be Riskier Than It Looks
Nov 09Market Cool On ProPhase Labs, Inc.'s (NASDAQ:PRPH) Revenues Pushing Shares 26% Lower
Jul 03Does This Valuation Of ProPhase Labs, Inc. (NASDAQ:PRPH) Imply Investors Are Overpaying?
Mar 04ProPhase Labs, Inc.'s (NASDAQ:PRPH) Business And Shares Still Trailing The Industry
Jan 09ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate
Sep 21Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt
Aug 11We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease
Apr 07ProPhase Labs (NASDAQ:PRPH) Seems To Use Debt Quite Sensibly
Jan 24ProPhase Labs: Small Cap Stock With Strong Fundamentals And Growth Potential
Oct 13ProPhase Labs Q2 2022 Earnings Preview
Aug 10We Think ProPhase Labs (NASDAQ:PRPH) Can Stay On Top Of Its Debt
Jul 26ProPhase Labs to license two investigational cancer compounds from Global BioLife
Jul 21ProPhase Labs: A Stellar Quarter And Another Special Dividend
May 16Shareholder Returns
| PRPH | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 13.6% | -1.9% | -1.1% |
| 1Y | -84.1% | 6.5% | 22.4% |
Return vs Industry: PRPH underperformed the US Pharmaceuticals industry which returned 7.9% over the past year.
Return vs Market: PRPH underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| PRPH volatility | |
|---|---|
| PRPH Average Weekly Movement | 17.2% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PRPH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PRPH's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 113 | Ted Karkus | www.prophaselabs.com |
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
ProPhase Labs, Inc. Fundamentals Summary
| PRPH fundamental statistics | |
|---|---|
| Market cap | US$15.21m |
| Earnings (TTM) | -US$27.76m |
| Revenue (TTM) | US$12.75m |
1.3x
P/S Ratio-0.6x
P/E RatioIs PRPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRPH income statement (TTM) | |
|---|---|
| Revenue | US$12.75m |
| Cost of Revenue | US$16.88m |
| Gross Profit | -US$4.13m |
| Other Expenses | US$23.63m |
| Earnings | -US$27.76m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.16 |
| Gross Margin | -32.38% |
| Net Profit Margin | -217.64% |
| Debt/Equity Ratio | 45.1% |
How did PRPH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 02:46 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ProPhase Labs, Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hunter Diamond | Diamond Equity Research LLC |
| Ashok Kumar | ThinkEquity LLC |